QualityStocks would like to highlight BrainStorm Cell Therapeutics (
OTCQB: BCLI), a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s Disease (PD). NurOwn™ is the company's proprietary, first-of-its-kind technology that induces autologous bone marrow-derived Mesenchymal Stem Cells (MSCs) to secrete Neurotrophic Factors (NTF). The NurOwn treatment approach is to transplant these “MSC-NTF” cells back into the patient at or near the site of damage, in the spine and/or muscles.
In the company’s news,
BrainStorm Cell Therapeutic has received notification from the European Patent Office (EPO) that it intends to grant to the company its patent application No. EP06766101.7.
This patent, entitled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases,” covers the method of production of the company’s proprietary technology that induces autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases.
BrainStorm’s proprietary NurOwn™ stem cell therapy was developed from this differentiation method.
“We are confident that strengthening our patent portfolio in the European Union, together with leveraging our Orphan Drug status there, will position us well when we pursue European marketing approval of our stem cell therapy,” Chaim Lebovits, president of BrainStorm, stated in the press release. “This is a very exciting moment for BrainStorm as this is our first patent to receive a notice of allowance in Europe. In the EU there are about 50,000 ALS patients.”
BrainStorm is the exclusive worldwide licensee of these technologies from Ramot, the technology transfer company of Tel Aviv University.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
